| Literature DB >> 26271099 |
Kwi Young Kang1, In Je Kim2, Min A Yoon3, Yeon Sik Hong1, Sung-Hwan Park4, Ji Hyeon Ju4.
Abstract
OBJECTIVE: To study the relationship between inflammatory and structural lesions in the sacroiliac joints (SIJs) on MRI and spinal progression observed on conventional radiographs in patients with axial spondyloarthritis (axSpA).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26271099 PMCID: PMC4535979 DOI: 10.1371/journal.pone.0135206
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of patients with axial spondyloarthritis.
| Parameter at baseline | Radiographic progression | |||
|---|---|---|---|---|
| Total (n = 110) | Absent (n = 85) | Present (n = 25) | p value | |
| Male (%) | 83 (75.5) | 62 (72.9) | 21 (84.0) | 0.303 |
| Age (years) | 31.6±10.6 | 29.3±9.8 | 39.6±9.5 | <0.001 |
| Age at diagnosis (years) | 28±10 | 26±10 | 36±10 | <0.001 |
| Duration since diagnosis (years) | 3.0±5.0 | 2.9±5.1 | 3.2±5.0 | 0.756 |
| HLA-B27 positive (%) | 97 (88.2) | 78 (91.8) | 19 (76) | 0.070 |
| Peripheral arthritis (%) | 63 (57.3) | 49 (57.6) | 14 (56.0) | 1.000 |
| Enthesitis (%) | 29 (26.4) | 24 (28.2) | 5 (20.0) | 0.606 |
| Uveitis (%) | 28 (25.5) | 21 (24.7) | 7 (28.0) | 0.796 |
| Family history (%) | 13 (11.8) | 11 (12.9) | 2 (8) | 0.729 |
| ESR (mm/hr) | 24.6±23.5 | 24.2±23.3 | 26.±24.4 | 0.443 |
| CRP (mg/l) | 11.8±19.5 | 10.5±19.5 | 16.2±19.1 | 0.051 |
| NSAIDs (%) | 100 (90.9) | 78 (91.8) | 22 (88.0) | 0.692 |
| Sulfasalazine (%) | 36 (32.7) | 32 (37.6) | 4 (16.0) | 0.053 |
| Methotrexate (%) | 38 (34.5) | 26 (68.2) | 12 (48.0) | 0.150 |
| TNF inhibitors (%) | 47 (42.7) | 32 (37.6) | 15 (60.0) | 0.065 |
| SASSS | 5.3±9.1 | 2.5±5.8 | 4.2±3.6 | <0.001 |
| SASSS ≥2 (%) | 50 (45.5) | 29 (34.1) | 21 (84.0) | <0.001 |
| Number of Syndesmophytes | 1.35±2.82 | 0.5±1.9 | 4.2±3.6 | <0.001 |
| Presence of syndesmophytes (%) | 29 (26.4) | 11 (12.9) | 18 (72.0) | <0.001 |
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAIDs, Non-steroidal anti-inflammatory drugs; TNF, tumor necrosis factor; SASSS, Stokes ankylosing spondylitis spine score
Baseline sacroiliac joint MRI findings in patients with axial spondyloarthritis (n = 110).
| MRI finding | Mean±SD score | N (%), score of>0 | ICC (95% CI) | |
|---|---|---|---|---|
| Acute inflammation | Bone marrow edema | 9.4±12.4 | 71 (65) | 0.95 (0.91–0.97) |
| Depth | 0.6±1.4 | 21 (19) | 0.94 (0.89–0.98) | |
| Intensity | 1.7±3.2 | 30 (27) | 0.92 (0.87–0.95) | |
| Structural lesions | Fat metaplasia | 4.6±7.8 | 51 (46) | 0.98 (0.97–0.99) |
| Erosion | 3.8±5.7 | 55 (50) | 0.85 (0.77–0.90) | |
| Backfill | 0.2±0.8 | 8 (7) | 0.57 (0.34–0.72) | |
| Ankylosis | 2.0±5.4 | 18 (16) | 0.98 (0.97–0.99) | |
MRI, magnetic resonance imaging; ICC, Interclass correlation coefficient
*ICC for each score between reader 1 and reader 2
Spinal radiographic progression over 2 years accoding to structural lesions in the sacroiliac joints observed on baseline MRI.
| SIJ MRI findings at baseline | Fat metaplasia | Erosion | Backfill | Ankylosis | ||||
|---|---|---|---|---|---|---|---|---|
| No (n = 59) | Yes (n = 51) | No (n = 55) | Yes (n = 55) | No (n = 95) | Yes (n = 15) | No (n = 89) | Yes (n = 21) | |
| Baseline SASSS | 2.5±4.5 | 8.6±11.7 | 8.2±11.6 | 2.4±4.2 | 5.6±9.4 | 2.0±2.3 | 2.5±4.5 | 19.6±12.9 |
| Presence of syndesmophytes at baseline | 0.5±1.5 | 2.3±3.6 | 2.3±3.6 | 0.4±1.2 | 1.4±2.9 | 0.3±0.7 | 0.5±1.3 | 5.7±4.2 |
| Change in the SASSS over 2 years | 0.3±1.1 | 2.2±3.9 | 1.7±3.6 | 0.6±1.9 | 1.3±3.0 | 0.4±0.7 | 0.8±2.7 | 3.0±3.1 |
| Change in number of syndesmophytes over 2 years | 0.1±0.5 | 0.7±1.5 | 0.6±1.4 | 0.2±0.6 | 0.4±1.1 | 0.1±0.4 | 0.2±1.3 | 0.8±1.6 |
Data are expressed as the mean±SD
MRI, magnetic resonance imaging; SIJ, sacroiliac joints; SASSS, Stoke Ankylosing Spondylitis Spine Score
* p<0.05 and
**<0.01 (comparison between two groups (absence vs. presence of each MRI finding)
Univariate and multivariate analysis of factors associated with radiographic spinal progression over 2 years.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
|
| 1.10 (1.05–1.15) | <0.001 | ||
|
| 0.28 (0.09–0.94) | 0.040 | ||
|
| 0.002 | 0.034 | ||
| 0 | Reference | Reference | ||
| 1–5 | 3.12 (0.89–10.90) | 0.076 | 2.00 (0.47–8.62) | 0.348 |
| ≥6 | 7.66 (2.49–23.56) | <0.001 | 5.66 (1.52–21.04) | 0.010 |
|
| 0.38 (0.15–0.98) | 0.045 | ||
|
| 6.42 (2.18–18.93) | 0.001 | ||
|
| 2.59 (1.04–6.44) | 0.040 | ||
|
| 17.30 (5.88–50.87) | <0.001 | 14.74 (4.71–46.14) | <0.001 |
|
| 0.32 (0.10–1.00) | 0.050 | ||
|
| 2.48 (1.00–6.19) | 0.051 | ||
OR, odds ratio; CI, confidence interval
*Present on baseline MRI of the sacroiliac joints
#Present on baseline X-rays of the lumbar spine
Fig 1Radiographic progression according to the severity of fat metaplasia on baseline sacroiliac joint (SIJ) MRI.
Spinal radiographic progression (scored according to the SASSS) was significantly greater in patients with severe fat metaplasia on baseline SIJ MRI after adjusting for baseline SASSS and TNF inhibitors treatment. P values were calculated using an analysis of covariance model, with the severity of fat metaplasia at baseline as a factor and the baseline SASSS and TNF inhibitors treatment as covariates. The bottom and top of the box were the first and third quartiles, and the band inside the box was the median. The ends of the whiskers represented 1.5 interquartiles.